Study of FKC289 for membranous nephropathy that has come back
This study tests a new treatment called FKC289 for people with membranous nephropathy (a kidney disease) that has not improved or has returned after other treatments. It aims to see if the treatment is safe and helps reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have membranous nephropathy confirmed by a kidney biopsy within the past 2 years
- Your disease has come back or has not responded to previous treatments
- You have a high level of a specific antibody (anti-PLA2R) in your blood
- You have high protein in your urine (more than 3.5 grams per day)
- You do not have an active infection or other serious health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This trial tests an experimental drug called YK012 for people with a serious type of kidney disease called primary membranous nephropathy. It aims to see if the drug is safe and helps when other treatments have stopped working.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This study tests a drug called telitacicept for people with a kidney condition called membranous nephropathy. It aims to see if the drug is safe and helps reduce protein in urine, protecting kidney function.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.